...
首页> 外文期刊>Internal medicine. >Successful Allogeneic Stem Cell Transplantation for Severe Aplastic Anemia after Treatment of Lymphoproliferative Disorder Caused by Rabbit Antithymocyte Globulin
【24h】

Successful Allogeneic Stem Cell Transplantation for Severe Aplastic Anemia after Treatment of Lymphoproliferative Disorder Caused by Rabbit Antithymocyte Globulin

机译:成功的异基因干细胞移植治疗严重的再生障碍性贫血后,兔抗胸腺细胞球蛋白引起的淋巴细胞增生性疾病

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Immunosuppressive therapy (IST) with a combination of antithymocyte globulin (ATG) and cyclosporine (CsA) is an effective therapeutic modality for patients with aplastic anemia (AA) who are not eligible for allogeneic stem cell transplantation (Allo-SCT) from a human leukocyte antigen-identical sibling donor. However, there have been reports of some patients developing lymphoproliferative disorder (LPD) after IST for AA. We herein report a case of a 26-year-old man with severe AA (SAA) complicated by LPD after a single course of IST, who was successfully treated with Allo-SCT from an unrelated donor. Two months after starting IST for SAA, he developed LPD in the stomach. CsA was reduced, however, his neutrophil counts decreased, and CsA could not be discontinued. The patient was treated with rituximab monotherapy, and LPD resulted in complete remission. However, he failed IST for SAA and underwent Allo-SCT with reduced-intensity conditioning to recover his hematopoiesis. The patient has achieved complete hematopoietic recovery without the recurrence of LPD for five years after transplantation. This is the first report of successful Allo-SCT for SAA after the treatment of LPD caused by the use of rabbit ATG. This case provides useful information for the management of SAA with the development of LPD after IST.
机译:结合抗胸腺细胞球蛋白(ATG)和环孢菌素(CsA)的免疫抑制疗法(IST)是再生障碍性贫血(AA)的患者(不适合从人白细胞进行同种异体干细胞移植(Allo-SCT)的患者)的有效治疗方式抗原相同的同胞供体。但是,有报道称一些患者在接受AA的IST治疗后发生了淋巴增生性疾病(LPD)。我们在此报告一例IST单疗程后并发LPD的严重AA(SAA)并发LPD的26岁男子,该患者已成功用来自无关供体的Allo-SCT治疗。在开始为SAA进行IST的两个月后,他在胃部发展了LPD。 CsA减少,但是他的中性粒细胞计数减少,并且不能停止使用CsA。该患者接受利妥昔单抗单药治疗,LPD导致完全缓解。然而,他在SAA的IST考试中不及格,并接受了强度降低的Allo-SCT来恢复造血功能。该患者在移植后的五年内已经实现了完全的造血恢复,并且没有LPD复发。这是在使用兔ATG引起的LPD治疗后成功应用SAA的Allo-SCT的首次报道。该案例为IST后LPD的发展为SAA的管理提供了有用的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号